New Research Collaboration Agreement (RCA) between the FDA-CDER (Center for Drug Evaluation and Research) and Chemotargets

15 January 2018

The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting the FDA’s mission of protecting public health.

 

Barcelona / Washington D.C., USA: The Food and Drug Administration's Center for Drug Evaluation and Research (FDA/CDER) and Chemotargets will work together under a 5-year Research Collaboration Agreement (RCA).

The primary objective of the research agreement will be to assess the utility and performance of the Chemotargets CLARITY® intelligence & discovery platform to predict on-target and off-target activities using known pharmacology and safety data from experimental studies of small molecular entities.  Evaluating in silico models for broad pharmacological profiling is of interest to CDER to predict potential adverse events of drugs in development. Additionally, insight into a chemical’s molecular target profile can help predict abuse and addiction potential, which may reduce risks associated with exposure to these substances.

The collaboration will involve the use of the Chemotargets CLARITY® platform to evaluate hypotheses on the toxicological endpoints that are used by CDER to evaluate drug safety. The program identifies the probable molecular targets and mode of action of small molecules, and their predicted metabolites by simultaneously and rapidly screening in a single predictive model more than 2,000 mechanisms of action associated with therapeutic activity and safety liabilities, including hundreds of safety-related mechanisms annotated with preclinical toxicity and clinical adverse effects. In this respect, Chemotargets CLARITY® enables predictive compound safety based on careful treatment of FAERS data and the use of some mathematical descriptors to highlight drug safety signals from background noise. CDER will have access to a Chemotargets CLARITY® version based on an expertly-curated training set derived from internal curation efforts and selected patent data from the GOSTAR database produced by Excelra to ensure a comprehensive coverage of the chemical space. Chemical structure drawing capabilities are available and supported via the Chemaxon Marvin JS.

 

About FDA CDER

FDA/CDER performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States.  As part of the FDA, CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs.  FDA/CDER's mission is to protect and promote public health by helping to ensure that human drugs are safe and effective, meet established quality standards, and are available to patients.

 

About Chemotargets

Founded on March 2006 as a spin-off company from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets offers cutting-edge validated computational methodologies with top-market predictive performance. The innovation strategy is driven by access to state-of-the-art research performed at Dr. Mestres Lab @ IMIM, a leading academic center of excellence based in Barcelona.

Dr. Mestres is the author of more than 150 peer reviewed publications. Chemotargets is currently recognized as a global leader in the provision of predictive analytics solutions to pharmaceutical and biotechnology companies and research institutions. Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient.

The recent strategic investment in Chemotargets by the Prous Institute for Biomedical Research will allow to accelerate product development and acquire new capabilities to support the company’s vision.

For more information: e-mail clarity@chemotargets.com

Chemotargets to Present at the Chem-Bio Informatics Society (CBI) Annual Meeting

Tokyo, Japan, October 24-27, 2017
02 October 2017

Chemotargets has been invited to speak at the Chem-Bio Informatics Society (CBI) Annual Meeting: “Drug Discovery and Development Pioneered by Data-Driven Research"” which takes place in Tokyo, Oct. 3-5, 2017.  

During the meeting, Dr. Jordi Mestres Ph.D.,  Chemotargets, Founder & President, will present two lectures:

“Chemotargets CLARITY: An Advanced Analytics Platform for Predictive Pharmacology and Safety”

The recent explosion of heterogenous data for millions of small molecules in a range of diverse areas of relevance to drug discovery offers a wealth of opportunities for using that data to build predictive models for pharmacology, safety and therapeutics but also poses challenges to develop advanced analytics tools that allow for visualizing its complexity in a highly compact and interpretable manner. Dr. Mestres will present the newly introduced platform Chemotargets CLARITY: an advanced analytics platform that allows for linking chemistry, pharmacology, and safety data.  During the seminar, several use cases will be presented, covering:

  • Extraction and visualization of pharmacology and safety data for small molecules available in public and patent databases
  • Prediction of the pharmacological profile of an early small molecule hit from HTS
  • Identification of potential safety liabilities due to the predicted off-target pharmacology
  • Prediction of metabolites and their pharmacological profiles as a source of safety liabilities
  • Exploiting the analytics tools provided to extract signals from all data generated

In his second presentation, “The Usefulness of In Silico Technologies to Minimize Off-Target Safety Pharmacology Events”, Dr Jordi Mestres will introduce specific examples in which comprehensive use of the in silico approach can support the design of an adequate off-target safety assessment strategy for novel investigational drugs.  Beyond the identification of simple structural alerts, access to pharmacological data for millions of small molecules, both from public and commercial sources, and post-marketing safety data for thousands of drugs, from the FDA Adverse Event Reporting System (FAERS), has allowed the development of a new generation of mechanism-based computational approaches to large-scale predictive drug safety. Applications to several use cases covering a variety of safety endpoints will be presented.

For further information or to schedule a meeting during the conference, please contact infochemo@chemotargets.com

About the Chem-Bio Informatics Society  

The Chem-BioInformatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society has interest in molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and its applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.    

About Chemotargets

Founded in March 2006 as a spin-off from Dr. Mestres’ Systems Pharmacology lab under the auspices of the IMIM, Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performan- ce.

The innovation strategy is driven by new cutting edge methods generated at Dr. Mestres’ lab at IMIM, a leading academic center of excellence based in Barcelona. Dr. Mestres is the author of more than 150 peer-reviewed publica- tions.

Chemotargets is currently recognized as a global leader in predictive analytics solutions for pharmaceutical and biotechnology companies and research institutions.

Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency.

Prous Institute for Biomedical Research’s recent strategic investment in Chemotargets will allow product development to be accelerated and new capabilities to be acquired in order to support the company’s vision.

Prous Institute Signs Investment Agreement With Chemotargets

Investment to expand Chemotargets portfolio of leading drug discovery solutions The transaction adds to a growing number of holdings of the Prous group in academic spin-off companies
06 June 2017

Barcelona, May 2017 – Prous Institute for Biomedical Research announced today that it has made a strategic investment in Chemotargets. Founded by Dr. Jordi Mestres as a spin-off of IMIM Hospital del Mar Medical Research Institute, Chemotargets is a global leader in the provision of predictive analytics solutions to pharmaceutical and biotechnology companies and research institutions. Financial terms of the transaction were not disclosed.

The investment will allow Chemotargets to expand its product development and accelerate its innovation plans in the drug discovery & development spaces. In addition, it will permit Chemotargets to grow its customer base and achieve a global presence in the pharmaceutical, healthcare and related industries.

As part of the agreement, Prous Institute will also leverage Chemotargets’ informatics solutions for its own drug discovery programs in the fields of cancer and neurodegeneration.

An immediate milestone of this agreement will be the introduction of a new big data analytics and visualization platform integrating chemistry, genomics, pharmacology, toxicology and therapeutics.

Big data is having an enormous impact in the finding of better and safer drugs. The use of advanced predictive analytics and visualization technologies enables the generation of new working hypotheses by seamlessly navigating within the enormous amount of data coming from modern biomedical research. Chemotargets’ platform optimizes research and development efforts by facilitating the existence of links between small molecules, their primary targets and secondary off-targets, the associated safety issues and the likely use in particular therapeutic areas.

Likewise, in the context of this transaction, the advanced computational approaches developed by Chemotargets will be evolved towards adapting the new platform to the new Precision Medicine paradigm.

“Chemotargets offers a state-of-the-art platform in its field and has a unique vision to develop it into a global solution for emerging applications in the life sciences, from initial drug discovery to clinical point of care” said Dr. Josep Prous, VP of Research & Development, Prous Institute. “We look forward to working closely with Dr Mestres’ team to maximize synergies and add value for customers.”

Dr. Jordi Mestres, Chemotargets' Founder & CEO commented: “We are very excited about this new partnership with Prous Institute which will allow us to accelerate our product development and innovation plans in the drug discovery space and continue to bring product upgrades and new enhancements to our growing number of end-users. Prous has over 50 years experience creating and managing biomedical knowledge and its reputation for the quality of its data and products is recognized worldwide. In this respect we highly value the agreement for what Prous will bring to Chemotargets beyond growth equity”.

Dr Joaquim Bellmunt, Director of IMIM, said: "Dr. Mestres is a Principal Investigator of IMIM and a pioneer in technology transfer within our Institution. We are delighted to see how our spin-off will be able to move to its next growth phase thanks to this strategic investment from Prous”.

 

About Prous Institute for Biomedical Research

Prous Institute for Biomedical Research is a privately-held research organization. It was founded as a spin-off of Prous Science, the leading scientific information provider (producer of Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, amongst others) acquired by Thomson Reuters in 2007. Based on its longstanding expertise in the creation and management of biomedical knowledge, the company has drug discovery programs in the fields of cancer and neurodegeneration, which has led to various preclinical candidates. Additionally, Prous Institute has invested in numerous companies in the field of life sciences including drug discovery, medical diagnostics, medical imaging or enabling technologies organizations.

About Chemotargets

Chemotargets S.L. is a computationally-oriented biotech company focused on the drug discovery and development areas. Located in Barcelona, it was founded in March 2006 as a spin-off initiative from the Chemogenomics Laboratory under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets' goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient. To this end, Chemotargets has designed, and continues to develop, an integrated technology platform involving a broad spectrum of cutting-edge computational methodologies.

About IMIM

The IMIM Hospital del Mar Medical Research Institute is a public body dedicated to scientific research in the field of Biomedicine and Health Sciences. Located at the Barcelona Biomedical Research Park (PRBB), IMIM is up to 82%, made up of research groups lead by professionals from the MAR Health Park, most of whom are associates of the Autonomous University of Barcelona (UAB) and the Pompeu Fabra University (UPF), as well as other seconded staff members from the Barcelona Institute for Global Health (ISGlobal), the Centre for Genomic Regulation (CRG), the Department of Experimental and Health Sciences of the Pompeu Fabra University (DCEXS-UPF), the Centre of Regenerative Medicine in Barcelona (CMRB) and the Barcelona Biomedical Research Park (PRBB).


For further information, please contact:

Atrevia
Mercè Mascarell
Tel. +34 93 419 06 30
MMASCARELL@ATREVIA.COM

Communication Department IMIM
Rosa Manaut
Tel. +34 618 509 885
RMANAUT@IMIM.ES